SI-BONE, Inc. (SIBN)

NASDAQ • Healthcare

$18.5

-$0.14 (-0.8%)

Market closed

Last close at September 4, 2026 at 20:00 UTC

Day Range$18.2 - $18.75

Avg. Volume (3M)501.2K

Market Cap$820.4M

52 Week Range

$11.48$21.89

Next EarningsIn 66 daysNov 9, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$56M100%

Gross Profitminus cost of goods$44.5M80%

In plain terms: out of every $100 in revenue, SI-BONE, Inc. currently loses $7.

Fundamentals & Financials

Revenue (TTM)

$213.6M

Net Income (TTM)

-$14.6M

EPS (TTM)

-$0.34

ROA (TTM)

-5.88%

Current Ratio

9.15

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+26.3%Q3 2025-$0.14

+31.3%Q4 2025-$0.11

+69.2%Q1 2026-$0.04

+41.2%Q2 2026-$0.1

+39.8%Q3 2026-$0.09

Nov 9

in 66 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About SI-BONE, Inc.

SI-BONE, Inc. develops and markets implantable solutions for musculoskeletal conditions in the sacropelvic region. Listed on the NASDAQ as SIBN, the company operates in medical devices and generated $200.9 million of revenue in FY2025. Its business centers on minimally invasive implants used to treat sacroiliac joint disorders, pelvic trauma, and related spine conditions.

Name

SI-BONE, Inc.

CEO

Laura A. Francis

Website

si-bone.com

Industry

Healthcare

Year Founded

2008

Employees

376

Today's Snapshot

AI-generated

The day ended with SIBN 0.8% lower at 18.50, in line with a weaker sector. Shares changed hands at about two-thirds of its usual level.

Trading Volume

Below 10d avg (551.4K)

382.4K

vs S&P 500 Today

Moderate Underperformance

-0.33%

Updated: September 4, 2026 at 20:11 UTC

Technical Indicators

4 Buy2 Neutral2 Sell

SIBN presents a mixed but overall constructive backdrop led by trend strength and longer-term moving average support while near-term momentum is weak. ADX is strong, signaling a pronounced trend even as short-term EMAs sit above the market and near-term momentum indicators show oversold readings and negative momentum, suggesting recent pullback behavior. The stock remains above its 50- and 200-day averages, which supports the buy stance, though on-balance volume is negative and the pivot lies slightly above the price. Technical takeaway: Buy — long-term trend support contrasts with short-term weakness and muted volume.

All signals